首页> 中国专利> FGFR2b抑制分子在制备治疗PAF介导的疾病药物中的应用

FGFR2b抑制分子在制备治疗PAF介导的疾病药物中的应用

页面导航

摘要
著录项
相似文献

摘要

本发明公开了FGFR2b抑制分子在制备治疗PAF介导的疾病药物中的应用。本发明是基于本发明发明人发现FGF‑7能诱导血小板活化因子PAF的产生所得到的研究成果。本发明发明人发现，PAF产生后能诱导促炎因子的水平上升，继而引发炎症反应，将抑制FGF‑7与FGFR2结合的分子作为FGF7的竞争性拮抗剂，结合FGF7特异受体FGFR2b，阻断FGFR2b激活为磷酸化FGFR2b，能有效抑制过度的炎症反应从而治疗ARDS症状，而且可以改善肺部纤维化。

著录项

公开/公告号CN111760026A

专利类型发明专利
公开/公告日2020-10-13

原文格式PDF
申请/专利权人汪炬;
展开▼

申请/专利号CN202010783944.6
发明设计人汪炬;
展开▼

申请日2020-08-06
分类号A61K45/00(20060101);A61K38/08(20190101);A61P11/00(20060101);A61P7/10(20060101);A61P9/10(20060101);A61P35/04(20060101);A61P25/28(20060101);A61P25/16(20060101);A61P31/04(20060101);A61P31/14(20060101);
代理机构44245 广州市华学知识产权代理有限公司;
代理人苏运贞
地址 510632 广东省广州市天河区黄埔大道西暨南大学生物科学技术学院7楼
入库时间 2023-06-19 08:33:20

相似文献

专利
中文文献
外文文献

1. FGFR2b抑制分子在制备治疗PAF介导的疾病药物中的应用 [P] . 中国专利： CN111760026A . 2020-10-13
2. 可诱导共刺激分子配体抑制剂在制备治疗乳腺癌疾病药物中的应用 [P] . 中国专利： CN110279859A . 2019-09-27
3. complement inhibitory molecule, antibody, fusion protein, nucleic acid molecule, vector, host cell, methods for making a complement inhibitory molecule or its functional equivalent or fusion protein, to identify a ligand of a complement inhibitory molecule , or a functional equivalent thereof, to treat an animal suffering from a complement-mediated disease or disorder, or to prevent an animal from developing a complement-mediated disease or disorder, to vaccinate an animal against a transmitted disease or disorder. by a hematophagous arthropod and to inhibit classical and alternative complement pathways in a non-human cell, tissue or organism, composition, use of a complement inhibitory molecule, a fusion protein or a nucleic acid molecule [P] . BRPI0410876A . 2006-07-04

机译：补体抑制分子，抗体，融合蛋白，核酸分子，载体，宿主细胞，制备补体抑制分子或其功能等同物或融合蛋白的方法，以鉴定补体抑制分子的配体或其功能等同物治疗患有补体介导的疾病或疾患的动物，或防止动物发展补体介导的疾病或疾患，为动物接种疫苗以抵抗传播的疾病或疾患。通过节血节肢动物并抑制非人类细胞，组织或生物体中的经典和替代补体途径，组成，补体抑制分子，融合蛋白或核酸分子的用途
4. methods of inhibiting cathepsin s chemotherapy-induced up-regulation, cathepsin s expression on the surface of tumor cells and angiogenesis in a cell group, tissue or organ, of treating neoplastic disease and a condition associated with cathepsin s activity in a patient, inducing antibody-dependent cell-mediated cytotoxic reaction against a tumor cell, killing tumor cells, identifying tumor cells in a cell population, and evaluating an individual's tumor cell response in vitro the presence of a chemotherapeutic agent, uses of a cathepsin inhibitor if a chemotherapeutic agent of cathepsin s, an anti-cathepsin s antibody or a fragment thereof and an antibody molecule, pharmaceutical composition, pharmaceutical kit and antibody molecule or a nucleic acid encoding said antibody molecule [P] . BRPI0710055A2 . 2011-08-02

机译：抑制组织蛋白酶化学诱导的上调，组织细胞或组织或器官中肿瘤细胞表面上组织蛋白酶的表达和血管生成的方法，用于治疗肿瘤性疾病和与患者组织蛋白酶活性有关的疾病，并诱导抗体依赖细胞介导的针对肿瘤细胞的细胞毒性反应，杀死肿瘤细胞，鉴定细胞群中的肿瘤细胞，并在体外评估是否存在化学治疗剂的情况下个体的肿瘤细胞反应，如果组织化学治疗剂使用组织蛋白酶抑制剂组织蛋白酶，抗组织蛋白酶抗体或其片段和抗体分子，药物组合物，药物试剂盒和抗体分子或编码所述抗体分子的核酸
5. Immunoconjugate, methods for treating multiple myeloma in an individual, for dispensing immunoconjugate-mediated drug, for inhibiting, delaying and / or preventing tumor development and / or dispensing malignant tumor cells in a patient in need thereof, for treating an individual having a condition and to decrease the amount of cells in direct or indirect contact with immunoconjugates, a method for treating multiple myeloma in an individual, to dispense immunoconjugate-mediated medication, to inhibit, delay and / or prevent tumor cell development in a cell culture, to inhibit, delay and / or prevent the development of a tumor and / or dispense malignant tumor cells in a patient in need thereof, to treat an individual having a condition and to decrease a number of cells in direct or indirect contact. with tumor cells, pharmaceutical composition, and kit. [P] . BRPI0821449A2 . 2015-06-16

机译：免疫缀合物，用于在个体中治疗多发性骨髓瘤的方法，用于分配免疫缀合物介导的药物，用于在需要其的患者中抑制，延迟和/或预防肿瘤的发展和/或分配恶性肿瘤细胞，用于治疗患有以下疾病的个体：为了减少与免疫缀合物直接或间接接触的细胞数量，一种用于治疗个体多发性骨髓瘤，分配免疫缀合物介导的药物，抑制，延迟和/或预防细胞培养中肿瘤细胞发展，抑制，在有需要的患者中延迟和/或预防肿瘤的发展和/或分配恶性肿瘤细胞，以治疗患有某种疾病的个体并减少直接或间接接触的细胞数量。带有肿瘤细胞，药物成分和试剂盒。